Значения термина cardiac cachexia на английском

These findings may pave the way for effective treatment approaches to cardiac cachexia.

Aetiology and the presence of cardiac cachexia did not influence the lipid profile.

The most dramatic metabolic problem in heart failure patients is the development of cardiac cachexia.

The available evidence suggests that cardiac cachexia is a multifactorial neuroendocrine and metabolic disorder with a poor prognosis.

Patients with cardiac cachexia suffer from generalised loss of lean tissue, fat tissue, as well as bone tissue.

Over the last decades, cardiac cachexia and alterations in muscle metabolism in heart disease have received increasing research interest.

Concerning the pathophysiology of cardiac cachexia, there is increasing evidence that neurohormonal and immune abnormalities may play a crucial role.

Background and aim: The prognostic impact of poor nutritional status and cardiac cachexia in myocardial infarction is not clearly understood.

While the mechanism(s) involved in the progression of cardiac cachexia is incompletely established, certain factors appear to be contributory.

This finding indicates that leptin may participate in the catabolic state leading to the development of cardiac cachexia in the course of CHF.

This study aimed to examine the influence of leptin on GHBP in CHF patients with and without cardiac cachexia compared with healthy control subjects.

A number of studies have also shown that cardiac cachexia is linked to raised plasma levels of inflammatory cytokines, such as tumor necrosis factor alpha.

Thus slowing or preventing the progression of cardiac cachexia relies heavily on dietary and exercise-based interventions in addition to standard heart failure treatments and medications.

Approximately 15% of elderly heart failure patients will eventually develop cardiac cachexia; such a diagnosis is closely associated with high morbidity and increased mortality.

It is hoped that a better understanding of the pathophysiological mechanisms involved in cardiac cachexia will lead to novel therapeutic strategies in the (near) future.

Cardiac cachexia is a co-morbidity that may develop in terminal stages of chronic heart failure (CHF).